Efficient Killing of Murine Pluripotent Stem Cells by Natural Killer (NK) Cells Requires Activation by Cytokines and Partly Depends on the Activating NK Receptor NKG2D by Gröschel, Carina et al.
July 2017 | Volume 8 | Article 8701
Original research
published: 26 July 2017
doi: 10.3389/fimmu.2017.00870
Frontiers in Immunology | www.frontiersin.org
Edited by: 
Martin Johannes Hoogduijn, 
Erasmus University Rotterdam, 
Netherlands
Reviewed by: 
Reem Al-Daccak, 
Institut National de la Santé et de la 
Recherche Médicale, France  
Gabriele Multhoff, 
Technische Universität 
München, Germany
*Correspondence:
Ralf Dressel  
rdresse@gwdg.de
†These authors have shared first 
authorship.
‡These authors have shared senior 
authorship.
Specialty section: 
This article was submitted to 
Alloimmunity and Transplantation, 
a section of the journal 
Frontiers in Immunology
Received: 14 May 2017
Accepted: 10 July 2017
Published: 26 July 2017
Citation: 
Gröschel C, Hübscher D, Nolte J, 
Monecke S, Sasse A, Elsner L, 
Paulus W, Trenkwalder C, Polic´ B, 
Mansouri A, Guan K and Dressel R 
(2017) Efficient Killing of Murine 
Pluripotent Stem Cells by Natural 
Killer (NK) Cells Requires Activation 
by Cytokines and Partly Depends on 
the Activating NK Receptor NKG2D. 
Front. Immunol. 8:870. 
doi: 10.3389/fimmu.2017.00870
efficient Killing of Murine Pluripotent 
stem cells by natural Killer (nK) 
cells requires activation by 
cytokines and Partly Depends on  
the activating nK receptor nKg2D
Carina Gröschel1,2†, Daniela Hübscher2,3†, Jessica Nolte4, Sebastian Monecke1,2,  
André Sasse1, Leslie Elsner1, Walter Paulus5, Claudia Trenkwalder6, Bojan Polic´ 7,  
Ahmed Mansouri5,8, Kaomei Guan3,9‡ and Ralf Dressel1,2*‡
1 Institute of Cellular and Molecular Immunology, University Medical Center Göttingen, Göttingen, Germany, 2 DZHK (German 
Center for Cardiovascular Research), Göttingen, Germany, 3 Department of Cardiology and Pneumology, University Medical 
Center Göttingen, Göttingen, Germany, 4 Institute of Human Genetics, University Medical Center Göttingen, Göttingen, 
Germany, 5 Department of Clinical Neurophysiology, University Medical Center Göttingen, Göttingen, Germany, 6 Department 
of Neurosurgery, University of Göttingen, Göttingen, Germany, 7 Department of Histology and Embryology, Faculty of 
Medicine, University of Rijeka, Rijeka, Croatia, 8 Department of Molecular Cell Biology, Max Planck Institute for Biophysical 
Chemistry, Göttingen, Germany, 9 Institute of Pharmacology and Toxicology, Technische Universität Dresden, Dresden, 
Germany
Natural killer (NK) cells play an important role as cytotoxic effector cells, which scan 
the organism for infected or tumorigenic cells. Conflicting data have been published 
whether NK  cells can also kill allogeneic or even autologous pluripotent stem cells 
(PSCs) and which receptors are involved. A clarification of this question is relevant 
since an activity of NK cells against PSCs could reduce the risk of teratoma growth 
after transplantation of PSC-derived grafts. Therefore, the hypothesis has been
tested that the activity of NK cells against PSCs depends on cytokine activation and 
specifically on the activating NK receptor NKG2D. It is shown that a subcutaneous 
injection of autologous iPSCs failed to activate NK cells against these iPSCs and can 
give rise to teratomas. In agreement with this result, several PSC lines, including two 
iPSC, two embryonic stem cell (ESC), and two so-called multipotent adult germline 
stem cell (maGSC) lines, were largely resistant against resting NK  cells although
differences in killing were found at low level. All PSC lines were killed by interleukin (IL)-
2-activated NK cells, and maGSCs were better killed than the other PSC types. The 
PSCs expressed ligands of the activating NK receptor NKG2D and NKG2D-deficient 
NK cells from Klrk1−/− mice were impaired in their cytotoxic activity against PSCs. The 
low-cytotoxic activity of resting NK cells was almost completely dependent on NKG2D. 
The cytotoxic activity of IL-2-activated NKG2D-deficient NK cells against PSCs was 
reduced, indicating that also other activating receptors on cytokine-activated NK cells 
must be engaged by ligands on PSCs. Thus, NKG2D is an important activating receptor 
involved in killing of murine PSCs. However, NK cells need to be activated by cytokines 
before they efficiently target PSCs and then also other NK receptors become relevant. 
These features of NK cells might be relevant for transplantation of PSC-derived grafts 
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since NK cells have the capability to kill undifferentiated cells, which might be present 
in grafts in trace amounts.
Keywords: teratoma, autologous transplantation, embryonic stem cells, induced pluripotent stem cells, 
multipotent adult germline stem cells, natural killer cells, cytokine-activated natural killer cells, natural killer 
receptor ligands
inTrODUcTiOn
Pluripotent stem cells (PSCs) hold a great potential for the 
therapy of diseases, which are currently incurable, including 
heart failure, Parkinson’s disease, and macular degeneration (1), 
since cellular grafts or even complex tissues can be generated 
in  vitro by directed differentiation of these cells (2). Clinical 
trials to evaluate the therapeutic potential of PSCs have been 
initiated (3, 4), and first encouraging results of studies using 
human embryonic stem cells (ESCs) (5) as source of grafts to 
treat macular degeneration (6–8) and heart failure (9) have been 
published.
Embryonic stem cell-derived grafts have to be transplanted in 
an allogeneic setting and, therefore, the rejection of ESC-derived 
allografts is a challenge for these new therapies. Although 
immunosuppressive therapy can efficiently prevent the rejection 
of allogenic organs, the persistent use of immunosuppressive 
drugs is associated with problems of toxicity and increased risks 
of infections and cancer. Therefore, other PSC types, which can 
be obtained from adult cells including so-called multipotent adult 
germline stem cells (maGSCs) (10) and induced pluripotent 
stem cells (iPSCs) (11–14) gained attention as potential source 
of autologous grafts. Autologous grafts should be transplant-
able without the need of immunosuppression, and recently, first 
results on the transplantation of retinal epithelial cells derived 
from autologous iPSCs have been reported (15). However, it is 
still debated whether grafts derived from iPSCs can be immu-
nogenic in syngeneic or autologous recipients (16, 17). While 
terminally differentiated grafts appear to be tolerated as expected 
(18–20), it has been reported that therapeutically relevant 
in vitro-differentiated human iPSC-derived grafts were at risk to 
be rejected in mice “humanized” with an “autologous immune 
system” depending on the direction of differentiation (21).
A further concern associated with the transplantation of 
PSC-derived grafts is the risk of tumorigenicity (22, 23). Notably, 
the risk of tumorigenicity might be even higher for iPSCs than 
ESCs due to mutations preexisting in the reprogrammed somatic 
cells, introduced during the reprogramming process or resulting 
from an increased genomic instability of iPSCs (24–26). However, 
all types of PSCs can give rise to teratomas. In immunodeficient 
mice, as few as 2 murine or 245 human ESCs were reported to 
elicit teratoma growth (27, 28). ESCs can also form teratomas 
in immunocompetent syngeneic recipients (29), although higher 
cell numbers appear to be required than in immunodeficient 
recipients (22, 30, 31). The risk of teratoma growth upon trans-
plantation of autologous iPSCs into immunocompetent recipients 
has not been assessed to our knowledge. However, in allogeneic 
immunocompetent hosts, PSCs are usually rejected and do not 
form teratomas (22, 31) although exceptions from this rule have 
been reported (32).
Natural killer (NK) cells have important effector functions 
such as cytotoxicity and cytokine production. The activity of 
NK cells is regulated by a plethora of germ-line encoded recep-
tors that recognize ligands on target cells (33). NK receptors 
include activating and inhibitory members. Inhibitory receptors 
of the Ly49 family in mice or the killer cell immunoglobulin-like 
receptor (KIR) family in humans interact with classical major 
histocompatibility complex (MHC) class Ia molecules, which are 
constitutively expressed on most cells (34, 35). In contrast, many 
activating receptors, including NKG2D (36), recognize ligands, 
which are mostly absent from healthy cells but become induced 
upon stress such as virus infection or malignant transformation 
(37). Classically, NK cells have been described as cells that, unlike 
cytotoxic T cells, do not require activation to exert cytotoxicity. 
However, stimulation with interleukin 2 (IL-2), IL-12, IL-15, 
IL-18, or combinations of these cytokines can markedly increase 
the activity of NK cells (38). While some targets such as the clas-
sical human NK cell target cell line K562 are efficiently killed also 
by resting NK cells, killing of others requires cytokine-activated 
NK cells (39).
Conflicting results have been published regarding the sus-
ceptibility of ESCs toward NK cells. Some studies have reported 
resistance or very low susceptibility (40, 41) while others found 
ESCs to be vulnerable to NK  cells (42, 43), and this might be 
due to differences in the activation status of the NK cells in these 
studies. We have shown previously that murine PSCs, including 
ESCs, iPSCs, and maGSCs, are targets for IL-2-activated NK cells 
in vitro (31, 44) and that NK cells can impair or even suppress 
the teratoma growth upon transplantation of the PSCs in  vivo 
(22, 44, 45). Murine PSCs are targets for allogeneic and syngeneic 
NK cells because they do not express MHC class I antigens, which 
serve as ligands for inhibitory NK receptors, at least at a level 
detectable by flow cytometry (31, 44, 46), but they do express 
ligands for activating NK receptors, such as NKG2D and DNAM-1 
(31, 42, 44). Similar expression patterns of ligands for activating 
NK receptors as on murine PSCs were found on human iPSCs, 
which were also targets of IL-2-activated allogeneic and autolo-
gous NK cells (39). Notably, human ESCs and iPSCs, in contrast 
to the respective murine cells, do express MHC class I molecules 
although in lower amounts than most differentiated cell types 
(39, 47). We have previously shown by inhibition experiments 
that killing of murine PSCs by IL-2-activated NK cells was partly 
dependent on NKG2D while killing of human iPSCs was more 
dependent on DNAM-1 (31, 39, 44).
Differentiation of PSCs usually increases the expression of 
MHC class I molecules (48, 49) and decreases the expression of 
NKG2D ligands (31, 44) and consequently in vitro-differentiated 
cells acquire resistance against NK cells (44). Thus, NK cells have 
the capability to target undifferentiated PSCs while ignoring dif-
ferentiated cells. NK cells might, therefore, increase the safety of 
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transplantations of PSC-derived grafts because they potentially 
increase the number of undifferentiated cells that can be tolerated 
in a graft. However, it needs to be clarified whether NK cells need 
activation by cytokines to target PSCs and which receptor–ligand 
interactions between NK cells and PSCs are important.
In this study, we set out to demonstrate that murine iPSCs 
can indeed form teratomas upon truly autologous transplanta-
tion and we tested whether NK  cells become activated in  vivo 
upon transplantation. Moreover, to resolve previous conflicting 
results, we directly compared the cytotoxic activity of resting and 
IL-2-activated NK  cells against PSCs, including ESCs, iPSCs, 
and maGSCs and analyzed the role of the activating NK receptor 
NKG2D by comparing wild-type and NKG2D-deficient NK cells.
MaTerials anD MeThODs
Mouse strains
C57BL/6, 129Sv, and NKG2D-deficient Klrk1−/− mice (50) as 
well as immunodeficient Rag2−/− and SCID/beige mice (C.B-
17/IcrHsd-scid-bg) were bred in the central facility for animal 
experimentation at the University Medical Center Göttingen 
under specific pathogen-free conditions in individually ventilated 
cages and in a 12  h light–dark cycle. The Klrk1−/− and Rag2−/− 
mice were on a C57BL/6 background. All animal experiments 
had been approved by the local government (Niedersächsisches 
Landesamt für Verbraucherschutz und Lebensmittelsicherheit) 
and were carried out in compliance with German and EU legisla-
tion (Directive 2010/63/EU).
stem cell lines and cell culture
Generation of New iPSC Lines
Tail biopsies were taken aseptically, cut into pieces, and incu bated 
in dispase solution (2 mg/ml, Thermo Fisher Scientific, Waltham, 
MA, USA) for 20 min at 37°C, washed with phosphate-buffered 
saline (PBS), and incubated again for 20 min at 37°C in 0.05% 
trypsin with 0.005% EDTA. After being washed, the isolated cells 
were cultured in Dulbecco’s modified Eagle’s medium (DMEM)/
F12 plus GlutaMAX™ (Thermo Fisher Scientific) supplemented 
with 10% fetal calf serum (FCS; selected batch, Lonza, Basel, 
Switzerland), 1× N2 supplement (Thermo Fisher Scientific), 1× 
non-essential amino acids (NEAA; Thermo Fisher Scientific), 
50  µM β-mercaptoethanol (β-ME; Promega, Mannheim, Ger-
many), 0.3  µg/ml hydrocortisone (Sigma-Aldrich, Munich, 
Germany), 10 ng/ml human epidermal growth factor (Peprotech, 
Rocky Hill, NJ, USA), 10 ng/ml human basic fibroblast growth 
factor (hbFGF, Peprotech), and 100 U/ml penicillin plus 100 µg/ml 
streptomycin (Thermo Fisher Scientific). Outgrowing fibroblasts 
were transduced with the STEMCCA virus (pHAGE2-EF1αFull-
hOct4-F2A-hKlf4-IHRES-hSox2-P2A-hc-Myc-W-loxP), which 
was kindly provided by Dr. Darrell Kotton, University of Boston. 
Cells transduced by the STEMCCA virus express the human 
pluripotency genes OCT4, KLF4, SOX2, and cMYC. Fibroblasts 
were transduced at a multiplicity of infection of 1 in 24-well-plates 
with 700 µl FIII medium [minimum essential medium α (MEMα; 
Thermo Fisher Scientific) with 4.5% FCS, 4.5% knockout serum 
replacement (Thermo Fisher Scientific), 50  µM β-ME, 0.35% 
d-(+)-glucose (Sigma-Aldrich), and 1,000 U/ml leukemia inhibi-
tory factor (LIF; Merck Millipore, Darmstadt, Germany)] and 
5  µg/ml polybrene (hexadimethrine bromide, Sigma-Aldrich). 
After culture for 24 h at 37°C, the virus was washed away and 
the cells were cultured for 5–7 days. Then, the cells were seeded 
on mitomycin C-inactivated mouse embryonic feeder cells in 
DMEM (Thermo Fisher Scientific) supplemented with 15% FCS, 
2 mM glutamine (Thermo Fisher Scientific), 1× NEAA, 50 µM 
β-ME, and 1,000 U/ml LIF as described previously (10). Single 
colonies of reprogrammed cells were picked to obtain stable cell 
lines for further analysis.
Culture of Stem Cell Lines
The ESC line MPI-II derived from a 129Sv mouse at the Max 
Planck Institute for Biophysical Chemistry (Göttingen, Germany) 
has been extensively characterized previously including the dem-
onstration of pluripotency by teratoma assays (31). After transfer 
of breeders of that colony to the University Medical Center 
Göttingen, a new ESC line (ESC BTL1) has been generated from 
a 129Sv embryo as described (51). In parallel, two iPSC lines were 
generated as described above, one from the same 129Sv colony 
(iPSC129Sv) and one from a C57BL/6J mouse (Janvier Labs, Le 
Genest Saint Isle, France). The maGSC lines, maGSC 129Sv, and 
maGSC C57BL/6 have been described earlier (10) and their pluri-
potency has also been demonstrated in teratoma assays (44). The 
well-characterized ESC R1 cell line (52) has been used as positive 
control for expression of pluripotency genes in quantitative PCR 
(qPCR) experiments.
Before the PSC lines were used as target cells for NK  cells, 
they were cultured on Geltrex-coated cell culture plates (333 µg/
T25 flask), prepared according to manufacturer’s instructions 
(Thermo Fisher Scientific) in DMEM supplemented with 10% 
FCS, 1× NEAA, 50 µM β-ME, and 1,000 U/ml LIF. For harvesting 
at 80% confluence, the cells were incubated in stem cell trypsin 
(0.25% trypsin, 0.02% EDTA, 0.1% glucose, 0.3% Tris–HCl in 
PBS) for several minutes at 37°C until dissociation of stem cell 
colonies occurred. A single cell suspension was prepared by dilut-
ing cells in 10 volumes of stem cell medium. Stem cells were tested 
by PCR assays prior to experiments to exclude fungal, bacterial, 
and mycoplasmal infections.
Culture of YAC-1 Cells
The murine T-lymphoma cell line YAC-1 (H2a), which was used 
as positive control for the cytotoxic activity of NK cells, was main-
tained in DMEM supplemented with 10% FCS, 2 mM glutamine, 
1 mM sodium pyruvate, 50 µM β-ME, 100 U/ml penicillin, and 
100 µg/ml streptomycin.
Pluripotency assays
Alkaline Phosphatase Staining and 
Immunofluorescence Staining of Pluripotency 
Marker Proteins
The alkaline phosphatase activity of PSCs was detected using a 
kit according to the manufacturer’s instructions (Sigma-Aldrich). 
Expression of marker proteins of PSCs (LIN28, NANOG, and 
SSEA1) was analyzed by immunofluorescence staining. The stem 
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cells were grown on cover-slips coated by 0.1% gelatin. The cells 
were fixed with 4% paraformaldehyde in PBS before blocking in 
1% bovine serum albumin solution. For detection of NANOG, 
the cells were permeabilized (0.1% Triton X-100, Sigma-Aldrich) 
for 10 min before incubation with the primary antibody (Ab). The 
primary Abs (Table S1 in Supplementary Material) were added 
in 100 µl PBS to the cover-slips and incubated for 1 h at 37°C in 
a humidified chamber. Afterward, the cover-slips were washed 
three times with PBS before the secondary Ab was added. After 
incubation for 1  h at 37°C, the cover-slips were washed again 
before nuclei were stained with 4′,6-diamidino-2-phenylindol 
(DAPI, 0.4 µg/ml, Sigma-Aldrich) for 10 min. The samples were 
mounted in Vectashield mounting medium (Vector Laboratories, 
Cambridgeshire, UK) and analyzed with the fluorescence micro-
scope Axio Observer Z1 (Zeiss, Jena, Germany) and Axio Vision 
4.6 software.
Immunoblotting for Detection of Pluripotency Marker 
Proteins
In ESC BTL1 cells, the pluripotency marker proteins OCT4, 
SALL4, SOX2, KLF4, and ZPF206 were detected by immunob-
lotting and α-tubulin served as loading control. The antibodies 
used are given in Table S1 in Supplementary Material, and the 
immunoblotting was done as described previously (53).
In Vitro Differentiation of iPSCs
For in vitro differentiation of iPSCs, the hanging drop method 
was applied. Hanging drops containing 300 cells in 20 µl Iscove’s 
modified Dulbecco’s medium plus GlutaMAX™ (Thermo Fisher 
Scientific) supplemented with 20% FCS, 1× NEAA, 450  µM 
α-Monothioglycerol (Sigma-Aldrich) were cultured for 2  days. 
In this time, embryoid bodies had formed and were subsequently 
transferred into Petri dishes for a 3-day suspension culture period 
before transfer to gelatinized (0.1%) cell culture dishes for further 
5, 15, or 25 days. Medium was exchanged every second or third 
day. The cells were harvested at the indicated time points, and 
expression of genes that indicate differentiation into the three 
germ layers was analyzed.
Reverse Transcription Polymerase Chain Reaction 
(RT-PCR) and qPCR for Expression Analysis of 
Pluripotency and Differentiation Genes
Total RNA was extracted from PSCs or in  vitro-differentiated 
cells, treated with DNase I to avoid contamination with genomic 
DNA, and used for cDNA synthesis as described previously (46). 
The analyzed genes and the primer pairs used are given in Table S2 
in Supplementary Material. The iPSC lines and their differentia-
tion products were analyzed by qualitative RT-PCR as described 
previously (10, 54). The expression of pluripotency genes in ESC 
BTL1 cells was determined by qPCR as described before (53).
Teratoma Assays
The PSCs were injected in 100 µl PBS subcutaneously into the 
flank of the mice. Tumor growth was monitored by palpation and 
size was recorded using linear calipers. Animals were sacrificed 
after 3 months or when a tumor volume of 1 cm3 was reached. 
The tumor volume was calculated by the formula V = πabc/2, 
where a, b, and c are the orthogonal diameters. Autopsies of all 
animals were performed and tumor tissues were immediately 
frozen in liquid nitrogen or directly placed in phosphate-
buffered formalin (30  mM NaH2PO4, 40  mM Na2HPO4, 4% 
formalin) for 16  h before being embedded in paraffin. Tissue 
sections (2.5 µm) were stained with hematoxylin and eosin for 
histological examination.
nK cells and cytotoxicity assay
Natural killer cells were isolated from spleens of C57BL/6 wild-
type and NKG2D-deficient Klrk1−/− mice by magnetic-activated 
cell sorting using a kit for negative selection (mouse NK Cell 
Isolation Kit II; Miltenyi Biotec; Bergisch-Gladbach, Germany) 
according to the manufacturer’s protocol. The proportion of 
NK cells in the spleens and the purity of the isolated CD49b+CD3− 
NK cells were always determined by flow cytometry and were 
similar in wild-type and NKG2D-deficient mice (Figure S1 in 
Supplementary Material). In parallel, we always confirmed 
the expression of NKG2D on CD49b+ wild-type NK  cells and 
the NKG2D-deficiency on Klrk1−/− CD49b+ NK  cells (data 
not shown). The purified NK cells were either directly used as 
cytotoxic effector cells (day 0) or after stimulation for 4 days with 
10 ng/ml mouse IL-2 (Immunotools, Friesoythe, Germany). The 
cytotoxic activity of the NK cells against the PSCs and YAC-1 
control cells was measured in 51Cr-release assays as described 
previously (45). The 51Cr-labeled target cells were exposed to the 
NK  cells in triplicates at several effector to target (E:T) ratios 
for 4 h. The E:T ratios always indicate the ratio of CD49b+CD3− 
effector cells to target cells. Spontaneous release of 51Cr was 
determined by incubation of target cells in the absence of effector 
cells and specific lysis was calculated by subtracting the sponta-
neous 51Cr-release.
Flow cytometry
Flow cytometry was performed on a FACS Calibur flow cytom-
eter (BD Biosciences, Heidelberg, Germany) using CellQuestPro 
data acquisition and analysis software. The Abs used for flow 
cytometry are described in Table S3 in Supplementary Material. 
Isotype controls were used for directly labeled monoclonal 
antibodies (mAbs). For staining, 5 × 105 cells were incubated in 
100 µl PBS with 1 µg of the respective primary mAb for 30 min 
at 4°C before washing with PBS. To detect the unlabeled mAbs, 
the cells were incubated subsequently in 100  µl PBS with 1  µl 
of a fluorescein isothiocyanate-labeled goat anti-rat IgG Ab (for 
anti-RAE-1, anti-MULT-1, and anti-H60). In these experiments, 
cells stained with the secondary reagent only served as control. 
The percentage of positive cells expressing the analyzed molecule 
and their mean fluorescence intensity (MFI) was determined by 
subtracting the values of the appropriate controls.
statistics
Results are shown as mean with SD or as mean with SEM for 
cytotoxicity assays. The data were evaluated with the SPSS soft-
ware (IBM, Armonk, NY, USA). Analyses of variance (ANOVA) 
adjusted for effector to target (E:T) ratios were used to evaluate 
the cytotoxicity data and Bonferroni tests were selected as post hoc 
FigUre 1 | Autologous induced pluripotent stem cell (iPSC) lines are pluripotent and can give rise to teratomas. (a) Fibroblasts (a) isolated from tail tip biopsies of 
C57BL/6J mice gave rise to colonies of iPSCs (b) upon transduction with the reprogramming vector. The colonies were positive for alkaline phosphatase (c). The 
scale bars indicate 50 µm. (B) Colonies of the iPSCs also expressed the pluripotency marker proteins SSEA1 (a, b), LIN28 (c, d), and NANOG (e, f) as demonstrated 
by immunofluorescence staining alone (a, c, e) or in combination with DAPI to counterstain nuclei (b, d, f). The scale bar indicates 25 µm. (c) Cells of the iPSC line 
1–2 were subcutaneously injected into the mouse that donated the fibroblast and a teratoma was obtained after 35 days. The mesodermal differentiation into 
cartilage (a), endodermal differentiation into intestinal epithelium (b), and ectodermal differentiation into neural rosettes (c) is shown. The scale bars indicate 100 µm.
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tests. A P-value of  ≤  0.05 in two-sided tests was considered 
significant.
resUlTs
no nK cell activation against autologous 
iPscs In Vivo
We generated fibroblasts from the tail tips of five C57BL/6J 
mice at the age of 11  days. They were transduced with the 
STEMCCA virus for reprogramming into iPSCs. Colonies of 
cells with PSC morphology, which were positive for alkaline 
phosphatase, were obtained from all transductions as exempli-
fied in Figure 1A. Single colonies were picked and iPSC lines 
were established from the five mice. These lines expressed the 
endogenous pluripotency genes Oct4, Sox2, Nanog, and Lin28 
(Figure S2A in Supplementary Material). They were positive 
for the pluripotency markers SSEA1, LIN28, and NANOG at 
the protein level as shown by immunofluorescence staining 
(Figure 1B). After in vitro differentiation via the hanging drop 
method, marker genes for differentiated cells were expressed, 
including Afp for the endodermal lineage, Mash1 for the ecto-
dermal linage, and Flk1 for the mesodermal lineage. Moreover, 
Myh6 expression was detected, which is expressed in cardio-
myocytes (Figure S2B in Supplementary Material).
Four iPSC lines from four different mice formed teratomas 
in immunodeficient recipients indicating successful reprogram-
ming of the fibroblasts into iPSCs (Figure S2C in Supplementary 
Material). These features are summarized in Table 1. The iPSCs 
were also injected subcutaneously into the respective donors of 
FigUre 2 | Natural killer (NK) cells of mice injected with autologous induced pluripotent stem cell (iPSCs) do not kill the respective iPSC line ex vivo. (a) Means and 
SD of triplets are displayed of the specific lysis of YAC-1 and iPSC 0–3 cells by NK cells derived from the donor mouse of this iPSC line, which had been injected 
with these cells and developed a teratoma. (B) Means and SD of triplets are shown of the specific lysis of YAC-1 and iPSC 8–7 cells by NK cells derived from the 
donor mouse of this iPSC line, which had been injected with these cells and developed no teratoma. (c) Means and SD of triplets are displayed of the specific lysis 
of YAC-1 and iPSC 9–2 cells by NK cells derived from the donor mouse of this iPSC line, which had been injected with these cells but developed no teratoma. (D) In 
parallel to the 51Cr-release assays, shown in panels (a–c), the expression of ligands of activating and inhibitory NK receptors was determined by flow cytometry and 
the percentage of cells expressing the indicated ligands is shown. (e) The expression intensity of the ligands is displayed as mean fluorescence intensity.
TaBle 1 | Features of induced pluripotent stem cell (iPSC) lines generated for testing teratoma growth in autologous recipients.
iPsc 
line
expression of 
pluripotency 
genes (mrna) 
expression of 
pluripotency 
markers 
(protein)
In vitro 
differentiation 
(expression of 
marker genes)
Teratoma in 
immunodeficient 
recipients (rag2−/−)
Teratoma in 
autologous 
recipient 
(c57Bl/6J)
Teratoma in 
syngeneic 
recipients 
(c57Bl/6J)
Teratoma in major 
histocompatibility complex-
matched allogeneic recipients 
(129 sv, h2b)
0–3 Yes Yes Yes 2/3 Yes 2/4 0/3
1–2 Yes Yes Yes 4/4 Yes 2/4 0/3
6–5 Yes Yes Yes 0/41 Yes 0/4 0/3
8–7 Yes Yes Yes 4/4 No 2/4 0/3
9–2 Yes Yes Yes nt2 No nt nt
1The iPSC 6–5 cells formed teratomas in two of two RAG2−/−γc−/− mice, which lack in addition to B and T cells also NK cells, and were thereby confirmed to be pluripotent.
2The abbreviation nt indicates not tested.
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the fibroblasts. In three of the five mice, the autologous iPSCs 
formed teratomas (Figure 1C). The iPSC lines were also injected 
in syngeneic (not autologous) C57BL/6J recipients (H2b) as well 
as into MHC-matched but otherwise allogeneic 129Sv mice 
(H2b). Teratomas were observed in about 40% of the syngeneic 
but none of the allogeneic recipients (Table 1).
From three of these mice injected with autologous iPSCs 
[two without (8–7 and 9–2) and one with a teratoma (0–3)], we 
obtained NK cells at the end of the experiment and tested their 
activity against the autologous iPSCs and the control cell line 
YAC-1 directly ex vivo without any further in vitro stimulation. 
The NK cells of all mice killed YAC-1 targets but failed to lyse 
the respective iPSC lines (Figures  2A–C) despite expressing 
ligands of activating NK receptors, including the NKG2D ligand 
RAE-1 and the DNAM-1 ligand CD155 and despite being largely 
negative for MHC class I molecules, which serve as ligands for 
inhibitory NK receptors of the Ly49 family (Figures 2D,E).
efficient Killing of Pscs requires 
cytokine-activated nK cells
We have previously shown that IL-2-activated NK  cells effi-
ciently kill PSCs, including iPSCs, ESCs, and maGSCs (44). 
However, the NK cells from the C57BL/6 mice, which had been 
injected with autologous iPSCs in this study, failed to kill the 
iPSCs, irrespective of whether they developed a teratoma or not. 
Therefore, we next compared the efficacy of resting and IL-2-
activated NK  cells against several PSC lines. These included 
an iPSC line from a C57BL/6 mouse and an iPSC line from a 
129Sv mouse, which were generated similarly by transduction 
FigUre 3 | Pluripotent stem cells (PSCs) are more susceptible to interleukin (IL)-2-activated natural killer (NK) cells than resting NK cells. (a) A summary of means 
and SEM of specific lysis of YAC-1 cells (n = 16), embryonic stem cells (ESCs) (n = 14), induced pluripotent stem cell (iPSCs) (n = 18), and multipotent adult 
germline stem cell (maGSCs) (n = 16) by freshly purified NK cells (day 0) is shown as determined by 51Cr-release assays. (B) A summary of means and SEM of 
specific lysis of YAC-1 cells (n = 12), ESCs (n = 12), iPSCs (n = 12), and maGSCs (n = 12) by IL-2-activated NK cells (day 4) is shown as determined by 51Cr-release 
assays. The cytotoxic activity of resting (day 0) and IL-2-activated NK cells (day 4) has been compared for (c) YAC-1 cells and (D) all PSCs together. P-values for 
the comparisons (2-way-analyses of variance adjusted for E:T ratios) are indicated.
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of fibroblasts with the STEMCCA virus. We also included a 
newly established ESC line from a 129Sv embryo (ESC BTL1) 
(Figure S3 in Supplementary Material) and the long-established 
ESC line MPI-II also derived from a 129Sv embryo (31). Two 
maGSC lines, one from a C57BL/6 and one from a 129Sv 
mouse, which have been previously described (10, 44), were 
also included in the experiments. The pluripotency of the new 
stem cell lines iPSC 129Sv, iPSC C57BL/6, and ESC BTL1 cells 
was demonstrated by their ability to differentiate in  vivo into 
derivatives of the three germ layers in teratoma assays (Figure 
S4 in Supplementary Material).
We purified NK cells from C57BL/6 mice and either stimu-
lated them for 4 days in vitro with IL-2 or used them directly 
at day 0 as effector cells in 51Cr-release assays against the PSCs 
and YAC-1 targets. Resting NK  cells (day 0) killed the target 
cells with different efficacy (P = 0.0001, ANOVA) (Figure 3A). 
The YAC-1 control target cells were more susceptible to resting 
NK cells than iPSCs (P = 9.47 × 10−6) and maGSCs (P = 0.0096) 
and there was a similar trend for ESCs (P = 0.0766, Bonferroni 
post hoc test). In a comparison of the PSC types only, a trend for 
variation in their susceptibility to resting NK  cells was found 
(P =  0.0575). Similarly, the four target types varied in killing 
by IL-2-activated NK cells at day 4 (P = 0.0003) (Figure 3B). 
The YAC-1 cells were less susceptible to activated NK cells than 
maGSCs (P =  0.0010, Bonferroni post hoc test). The suscepti-
bility of the PSC types only also varied (P =  0.0007), and the 
post hoc test indicated a higher killing of maGSCs than iPSCs 
(P = 0.0006) and ESCs (P = 0.0389). Thus, maGSCs were more 
susceptible to resting and activated NK cells than the other PSC 
types.
The comparison of the susceptibility of the targets to 
resting and cytokine-activated NK  cells indicated that the 
YAC-1 cells were more susceptible to IL-2-activated NK  cells 
(P =  6.91 ×  10−6) (Figure  3C), similarly also the PSCs were 
overall significantly better lysed by IL-2-activated than by rest-
ing NK cells (P = 9.26 × 10−35) (Figure 3D). This difference was 
confirmed for all three types of PSCs in separate analyses (Figure 
S5 in Supplementary Material).
The cytotoxic activity of resting nK cells 
against Pscs Depends on the activating 
nK receptor nKg2D
In inhibition experiments with recombinant NKG2D-Fc pro-
teins, we have found previously that the killing of PSCs by IL-2-
activated NK cells partly depends on the activating NK receptor 
NKG2D (31, 44). To verify this result and to compare resting 
and IL-2-activated NK  cells, we used NKG2D-deficient mice 
(Klrk1−/−) as NK cell donors in addition to the wild-type mice. 
Resting NKG2D-deficient NK  cells were significantly impaired 
in killing of YAC-1 target cells (Figure 4A). The PSC lines were 
hardly killed and overall more resistant to NKG2D-deficient than 
to wild-type NK cells (P = 4.47 × 10−19) (Figure 4B). The separate 
analysis of the three PSC types revealed that all types were sig-
nificantly more resistant to NKG2D-deficient than to wild-type 
NK cells (Figures 4C–E).
The cytotoxic activity of cytokine-
activated nK cells against Pscs Depends 
Partly on nKg2D
The cytotoxicity of IL-2-activated NK cells against YAC-1 cells 
was largely dependent on NKG2D (P = 5.57 × 10−5) (Figure 4F). 
Overall, also the lysis of PSCs by NKG2D-deficient NK  cells 
FigUre 4 | Pluripotent stem cells (PSCs) are largely resistant against resting NKG2D-deficient natural killer (NK) cells, whereas the cytotoxic activity of interleukin-
2-activated NK cells depends only partly on NKG2D. The cytotoxic activity of resting wild-type (wt) and NKG2D-deficient (Klrk1−/−) NK cells has been compared for 
(a) YAC-1 cells (wt: n = 8, Klrk1−/−: n = 8), (B) all PSCs together (wt: n = 24, Klrk1−/−: n = 24), (c) embryonic stem cells (ESCs) (wt: n = 7, Klrk1−/−: n = 7),  
(D) induced pluripotent stem cells (iPSCs) (wt: n = 9, Klrk1−/−: n = 9), and (e) multipotent adult germline stem cell (maGSCs) (wt: n = 8, Klrk1−/−: n = 8). The 
cytotoxic activity of IL-2-activated wt and Klrk1−/− NK cells has been compared for (F) YAC-1 cells (wt: n = 6, Klrk1−/−: n = 6), (g) all PSCs together (wt: n = 18, 
Klrk1−/−: n = 18), (h) ESCs (wt: n = 6, Klrk1−/−: n = 6), (i) iPSCs (wt: n = 6, Klrk1−/−: n = 6), and (J) maGSCs (wt: n = 6, Klrk1−/−: n = 6). P-values for the 
comparisons (2-way-analyses of variance adjusted for E:T ratios) are indicated.
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FigUre 5 | Analysis of the expression of NKG2D ligands on target cells.  
(a) The percentage of cells expressing the indicated NKG2D receptor ligands 
(mean plus SEM) is shown as determined by flow cytometry in 3–13 
individual experiments [YAC-1: n = 13, embryonic stem cell (ESC) BTL1: 
n = 3, ESC MPI-II: n = 7, induced pluripotent stem cell (iPSC) 129Sv: n = 5, 
iPSC C57BL/6: n = 7, multipotent adult germline stem cell (maGSC) 129Sv: 
n = 6, maGSC C57BL/6: n = 7]. (B) The mean fluorescence intensity has 
been determined in parallel and is displayed plus SEM.
TaBle 2 | Summary of the expression of NKG2D ligands and major 
histocompatibility complex class I molecules on pluripotent stem cells and YAC-1 
cells.
cell line rae-1 MUlT-1 h60 h2Db h2Kb
YAC-1 +++1 ++ ++ nt2 nt
ESC BTL1 +++ + – –
ESC MPI-II +++ – – –
iPSC 129Sv ++ – – –
iPSC C57BL/6 ++ – – –
maGSC 129Sv +++ – – –
maGSC C57BL/6 ++ – – – –
1The symbol +++ indicates that on average the log10(%-positive cells × mean 
fluorescence intensity) is ≥3, ++ is <3 and ≥2, + is <2 and ≥1, and − is <1.
2The abbreviation nt indicates not tested. YAC-1 cells carry the H2a haplotype.
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was reduced (P = 6.11 × 10−7) (Figure 4G). Although the IL-2-
activated NK cells were less dependent on NKG2D than resting 
NK cells, the killing of ESCs, iPSCs, and maGSCs by NKG2D-
deficient NK cells was lower than the killing by wild-type IL-2-
activated NK cells (Figures 4H–J).
individual Psc lines Vary in Their 
susceptibility to nK cells independent of 
the stem cell Type
Separate analyses of the single PSC lines for their susceptibility 
to resting and IL-2-activated wild-type and NKG2D-deficient 
NK  cells are shown in the Figure S6 in Supplementary 
Material. The six PSC lines included in the analysis varied 
in their susceptibility to IL-2-activated NK cells (P = 0.0010, 
ANOVA), but to resting NK  cells only with borderline sig-
nificance (P  =  0.0634, ANOVA). The maGSC 129Sv cells 
were killed better by IL-2-activated NK cells than ESC MPI-II 
(P =  0.0078) and iPSC 129Sv cells (P =  0.0092, Bonferroni 
post  hoc test). All cell lines were more susceptible to IL-2-
activated NK  cells than resting NK  cells and the cytotoxic 
activity of resting NK cells toward all PSC lines was NKG2D-
dependent. However, only for ESC BTL1, maGSC 129Sv, and 
maGSC C57BL/6 cells the killing by IL-2-activated NK cells 
was significantly impaired by NKG2D deficiency (Figure S6 
in Supplementary Material).
The Psc lines express nKg2D ligands
The PSC lines expressed the NKG2D ligands RAE-1, MULT-1, 
and H60 in variable amounts as determined by flow cytometry 
in parallel to the cytotoxicity assays (Figure  5). On average 
more than 50% of the ESC BTL1, ESC MPI-II, and maGSC 
129Sv cells expressed RAE-1 (Figure  5A) and the MFI of 
RAE-1 (21.6, 36.6, and 36.6) was higher than for some other 
PSC lines, such as iPSC 129Sv (4.9) (Figure 5B). Taking into 
account the proportion of positive cells and the MFI, these 
data are summarized in Table 2. The expression of MHC class I 
molecules (H2Db and H2Kb) has also been determined and the 
newly established PSC lines were negative similarly as the old 
lines (Table 2), which had been tested also in previous studies 
(31, 44, 46). This expression pattern fits well to the observation 
that the killing of these cell lines by IL-2-activated NK cells was 
in part dependent on NKG2D. However, the lowest expression 
of NKG2D ligands was observed on the maGSC C57BL/6 cells 
but their killing by IL-2-activated NKG2D-deficient NK cells 
was also clearly reduced. Thus, further factors appear to con-
tribute to these variations and lack of inhibition by inhibitory 
NK receptors, which bind to MHC class I molecules is presum-
ably one of them.
DiscUssiOn
It is well-known that ESCs can form teratomas not only in 
immunodeficient but also in immunocompetent syngeneic 
hosts (29, 31). Therefore, it is reasonable to expect that iPSCs 
will form teratomas upon transplantation into autologous recipi-
ents, although this has previously not been demonstrated to our 
knowledge. In this study, we have shown that murine iPSCs 
derived from fibroblasts indeed can form teratomas in the indi-
vidual mice from which the fibroblasts have been taken. Notably, 
teratomas are regularly formed in syngeneic immunocompetent 
recipients although syngeneic NK cells can attack PSCs (31, 44). 
When we compared the teratoma growth upon subcutaneous 
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injections of ESC MPI-II cells into immunocompetent synge-
neic 129Sv mice and immunodeficient SCID mice, which have 
no B and T cells, and SCID/beige mice, which in addition lack 
also functional NK  cells, we found that the teratoma growth 
was similarly impaired in 129Sv and SCID mice compared to 
SCID/beige mice (22). Moreover, depletion of NK cells in SCID 
mice supported the early outgrowth of teratomas after injection 
of PSCs (44). These results demonstrated that NK cells indeed 
impair teratoma growth but are not sufficient to completely 
prevent tumors if high enough numbers of PSCs are injected. 
Activation of NK cells in vivo by poly I:C further reduced the 
teratoma frequency and size in SCID but not in SCID/beige 
recipients (44), suggesting that the activation status of NK cells 
is important for the outcome. Importantly, in vitro-differentiated 
cells have been shown to acquire resistance to NK  cells (44), 
and therefore, PSCs are expected to escape finally the NK cell-
mediated rejection by differentiation into other cell types which 
then form the teratoma.
The autologous transplantations of iPSCs performed in this 
study did not lead to a significant cytotoxic activity of NK cells 
against the autologous iPSCs. This was observed similarly in one 
mouse that developed a teratoma and in two recipients without a 
teratoma. We have recently shown that NK cells impair the out-
growth of teratomas from maGSCs not only in the subcutaneous 
tissue but also after transplantation into a therapeutically rel-
evant tissue such as the myocardium (45). In these experiments, 
it turned out that the operation procedure, which included an 
open chests surgery, was substantially increasing the cytotoxic 
activity of NK cells up to 4 weeks after transplantation (45). The 
subcutaneous injections of the autologous iPSCs performed 
in the experiments reported here, produced presumably less 
inflammatory responses than a major surgery and consequently 
did not activate NK cells against the iPSCs at least at the time 
point when the mice were sacrificed. However, individual dif-
ferences might exist since NK cells from mouse 0–3 showed a 
higher cytotoxic activity against YAC-1 control target cells than 
the NK cells of the other two recipients of autologous iPSCs (8–7, 
9–2). NK cells of these two mice killed YAC-1 cells to a similar 
extent as NK cells from untreated control C57BL/6 mice that we 
have analyzed previously (45).
Taking the importance of the activation status of NK cells 
into account, we now directly compared the cytotoxic activ-
ity of resting and IL-2-activated NK cells against PSCs. As in 
our previous studies (31, 44), all PSC lines, including ESCs, 
iPSCs, and maGSCs, were targets for IL-2-activated NK cells. 
However, they were much less attacked by resting than 
activated NK  cells. The maGSCs appeared to be killed even 
better than ESCs and iPSCs by activated NK cells but differ-
ences of individual PSC lines might be more important for 
this finding than principal differences between the PSC types. 
The finding that murine PSCs are good targets for cytokine-
activated NK cells but are killed less by resting NK cells likely 
explains why some early studies reported resistance of ESCs 
to NK  cells (40, 41) while we and others found them to be 
susceptible to cytokine-activated NK  cells (31, 42, 44). The 
result is also in agreement with our findings on human iPSCs, 
which were killed by allogeneic and syngeneic IL-2-activated 
NK  cells but much less by resting NK  cells (39), and with 
results reported by others for human cardiac-derived stem/ 
progenitor cells (55).
Murine PSCs do not express MHC class I molecules at 
least at a level that is readily detectable by flow cytometry (31, 
44, 46). MHC class I molecules function as ligands mainly 
for inhibitory NK receptors of the Ly49 family in mice (35). 
Cells that lack MHC class I molecules cannot inhibit NK cell 
activity and can, therefore, become targets of NK  cells (56). 
Importantly, the activity of NK cells is regulated by the balance 
of inhibitory and activating signals received via inhibitory 
and activating NK receptors (37). One of the most important 
activating NK receptor is NKG2D that interacts with a group 
of stress-inducible ligands including the RAE-1 and H60 
families and MULT-1 in the mouse (36, 57). We and others 
have shown that murine ESCs are among the few cell types 
that constitutively express NKG2D ligands (31, 42). In addi-
tion to ESCs, also iPSCs and maGSCs express variable patterns 
of NKG2D ligands mainly of the RAE-1 family and ligands 
of further activating NK receptors including the DNAM-1 
ligands CD112 and CD155 (44). The system of NKG2D and 
NKG2D ligands has been shown to be highly important for 
tumor immunity (58). It also affects the outcome of hemat-
opoietic stem cell transplantation (59–62) and solid organ 
transplantation (63, 64). NKG2D has also been reported to be 
involved in the rejection of neural progenitor cells by NK cells 
(65). In inhibition experiments with a recombinant NKG2D 
protein, we have previously shown that the killing of murine 
ESCs (31) and other PSCs (44) by IL-2-activated NK  cells is 
partly dependent on NKG2D. Here, we have confirmed this 
finding by comparing the activity of wild-type and genetically 
NKG2D-deficient NK cells. Notably, the killing of some indi-
vidual PSC lines appeared to depend little on NKG2D while 
killing of others was clearly affected by NKG2D-deficiency. 
Thus, the only partial inhibition of killing by recombinant 
NKG2D, which we observed in previous experiments, was 
not due to an incomplete inhibition of NKG2D activity and 
other activating NK receptors than NKG2D must contribute 
to the recognition of PSCs by activated NK  cells. DNAM-1 
is an obvious candidate among others because especially the 
ligand CD155 is prominently expressed on PSCs including 
the autologous iPSCs used in this study. Moreover, we have 
recently shown that the killing of human iPSCs by NK cells is 
mediated in part by DNAM-1 (39). The killing of human iPSCs 
was not dependent on NKG2D with exception of one combina-
tion of a specific iPSC line and an individual NK  cell donor 
(39). Thus, individual variations in NK receptor–ligand inter-
action need to be considered for their implications on human 
transplantations.
This potential individual variation in recognitions of PSCs 
by NK  cells is further emphasized by results obtained with 
human ESCs that have been engineered not to express β2-
microglobulin (66). In contrast to murine PSCs, human ESCs 
as well as iPSCs do express significant amounts of MHC class I 
molecules (39, 47). The β2-microglobulin and, therefore, also 
MHC class I-deficient human ESCs were killed more efficiently 
by NK  cells than wild-type ESCs (66). This demonstrates 
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the relevance of NK  cell inhibition via human MHC class I 
molecules recognized by inhibitory KIRs on human NK cells. 
Recognition of human MHC class I molecules by KIRs shows 
a considerable variability (34) and the activity of NK  cells 
toward allogeneic PSCs and their differentiation products 
can, therefore, be expected to vary depending on the MHC 
polymorphism of the PSCs and the KIR polymorphism of the 
recipients.
Notably, the low cytotoxic activity of resting NK cells against 
PSCs, which we observed, was almost completely depend on 
NKG2D in all investigated PSC lines. Therefore, any in  vivo 
activity of NK cells against PSCs under non-inflammatory con-
ditions must be expected to depend largely on the recognition of 
NKG2D ligands by NKG2D at least in murine transplantation 
models. Subcutaneous injections of PSCs presumably cause lit-
tle inflammatory responses compared to, e.g., intramyocardial 
injections by open chest surgery. Nonetheless, we observed 
measurable effects of NK cells on the teratoma growth kinetics 
after injection of PSCs in both models (44, 45). Thus, also the low 
largely NKG2D-dependent cytotoxic activity of resting NK cells 
against PSCs appears to be relevant in vivo. It might be highly 
important if PSCs would be present in trace amounts among 
in  vitro-differentiated cells intended for grafting. If NK  cells 
contribute to a fail-safe system against the tumorigenicity of 
PSCs after transplantation (67), this system might largely rely 
on NKG2D.
As a caveat, it should be mentioned that the initial step or 
even steps of differentiation of PSCs in vivo must not immedi-
ately remove the risk of tumorigenicity associated with PSCs but 
it could alter the recognition of the differentiated cells by the 
immune system and particularly NK cells. When we transplanted 
the murine ESC line MPI-II into rats immunosuppressed with 
cyclosporine A, no teratomas occurred likely due to the rejection 
of the ESCs by NK cells (31) which are not suppressed by cyclo-
sporine A in their activity against PSCs (45). However, when 
the same numbers of neuronal cells with a purity of more than 
95% that were obtained from these ESCs by a directed in vitro 
differentiation protocol were injected, we observed teratomas in 
61% of the recipients (31). Thus, a cell type in the differentia-
tion culture that differed from the original ESCs by resistance 
to NK  cells but that retained pluripotency presumably caused 
the tumors in these experiments. Therefore, it is important to 
carefully investigate the individual immunological properties 
of any graft that is evaluated in preclinical animal models or in 
clinical studies. Differentiation of PSCs into progenitor cells with 
a limited differentiation potential, e.g., neural progenitor cells, 
might be a strategy to significantly reduce the risk of tumori-
genicity (68).
cOnclUsiOn
Transplantation of autologous iPSCs can lead to teratomas as 
formally demonstrated here in a murine model to our knowl-
edge for the first time. Transplantation of grafts derived from 
autologous iPSCs into immunocompetent recipients as well as 
grafts derived from allogeneic PSCs into immunosuppressed 
or immunomodulated recipients has the unavoidable risk of 
tumorigenicity if undifferentiated or not sufficiently differenti-
ated cells are present in the grafts. The cytotoxic activity of 
NK cells against PSCs might reduce this risk although NK cells 
need to be activated by cytokines to exhibit a high cytotoxicity 
against PSCs. The IL-2-activated NK cells killed PSCs in a partly 
NKG2D-dependent manner while the low killing of PSCs by 
resting NK cells was almost completely dependent on NKG2D. 
Thus, any activity of NK  cells against PSCs present in grafts 
transplanted under non-inflammatory conditions, which fail to 
produce NK cell-activating cytokines, will presumably depend 
largely on NKG2D at least in murine models. The analysis of 
the activity of cytokine-activated NK  cells against PSCs and 
of the receptors involved might allow for the development of 
immunomodulatory protocols, which stimulate NK  cells to 
function efficiently as safeguard against undifferentiated PSCs 
in PSC-derived grafts.
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